These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

438 related items for PubMed ID: 22144343

  • 1. Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis.
    Planas R, Jelčić I, Schippling S, Martin R, Sospedra M.
    Eur J Immunol; 2012 Mar; 42(3):790-8. PubMed ID: 22144343
    [Abstract] [Full Text] [Related]

  • 2. Anti-JC virus antibodies in a large German natalizumab-treated multiple sclerosis cohort.
    Trampe AK, Hemmelmann C, Stroet A, Haghikia A, Hellwig K, Wiendl H, Goelz S, Ziegler A, Gold R, Chan A.
    Neurology; 2012 May 29; 78(22):1736-42. PubMed ID: 22592369
    [Abstract] [Full Text] [Related]

  • 3. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C.
    N Engl J Med; 2012 May 17; 366(20):1870-80. PubMed ID: 22591293
    [Abstract] [Full Text] [Related]

  • 4. Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
    Stüve O, Marra CM, Bar-Or A, Niino M, Cravens PD, Cepok S, Frohman EM, Phillips JT, Arendt G, Jerome KR, Cook L, Grand'Maison F, Hemmer B, Monson NL, Racke MK.
    Arch Neurol; 2006 Oct 17; 63(10):1383-7. PubMed ID: 17030653
    [Abstract] [Full Text] [Related]

  • 5. Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab.
    Sørensen PS, Bertolotto A, Edan G, Giovannoni G, Gold R, Havrdova E, Kappos L, Kieseier BC, Montalban X, Olsson T.
    Mult Scler; 2012 Feb 17; 18(2):143-52. PubMed ID: 22312009
    [Abstract] [Full Text] [Related]

  • 6. A second-generation ELISA (STRATIFY JCV™ DxSelect™) for detection of JC virus antibodies in human serum and plasma to support progressive multifocal leukoencephalopathy risk stratification.
    Lee P, Plavina T, Castro A, Berman M, Jaiswal D, Rivas S, Schlain B, Subramanyam M.
    J Clin Virol; 2013 Jun 17; 57(2):141-6. PubMed ID: 23465394
    [Abstract] [Full Text] [Related]

  • 7. Immune responses to JC virus in patients with multiple sclerosis treated with natalizumab: a cross-sectional and longitudinal study.
    Jilek S, Jaquiéry E, Hirsch HH, Lysandropoulos A, Canales M, Guignard L, Schluep M, Pantaleo G, Du Pasquier RA.
    Lancet Neurol; 2010 Mar 17; 9(3):264-72. PubMed ID: 20117055
    [Abstract] [Full Text] [Related]

  • 8. Multiple sclerosis, natalizumab, and PML: helping patients decide.
    Rudick RA.
    Cleve Clin J Med; 2011 Nov 17; 78 Suppl 2():S18-23. PubMed ID: 22123928
    [Abstract] [Full Text] [Related]

  • 9. Nearly one-half of Brazilian patients with multiple sclerosis using natalizumab are DNA-JC virus positive.
    Fragoso YD, Mendes MF, Arruda WO, Becker J, Brooks JB, Carvalho Mde J, Comini-Frota ER, Domingues RB, Ferreira ML, Finkelsztejn A, Gama PD, Gomes S, Gonçalves MV, Kaimen-Maciel DR, Morales Rde R, Muniz A, Ruocco HH, Salgado PR, Albuquerque LB, Gama RA, Georgeto S, Lopes J, Oliveira CL, Oliveira FT, Safanelli J, Saldanha PC, Satomi M.
    Arq Neuropsiquiatr; 2013 Oct 17; 71(10):780-2. PubMed ID: 24212514
    [Abstract] [Full Text] [Related]

  • 10. Reply to "'Thinking without thinking' about natalizumab and PML".
    Houff S, Berger JR.
    J Neurol Sci; 2008 Jan 15; 264(1-2):198-9; author reply 199. PubMed ID: 17936798
    [No Abstract] [Full Text] [Related]

  • 11. The effect of plasma exchange on serum anti-JC virus antibodies.
    Subramanyam M, Plavina T, Khatri BO, Fox RJ, Goelz SE.
    Mult Scler; 2013 Jun 15; 19(7):912-9. PubMed ID: 23232602
    [Abstract] [Full Text] [Related]

  • 12. Does risk stratification decrease the risk of natalizumab-associated PML? Where is the evidence?
    Cutter GR, Stüve O.
    Mult Scler; 2014 Sep 15; 20(10):1304-5. PubMed ID: 24812045
    [Abstract] [Full Text] [Related]

  • 13. Molecular diagnostic tests to predict the risk of progressive multifocal leukoencephalopathy in natalizumab-treated multiple sclerosis patients.
    Rossi F, Newsome SD, Viscidi R.
    Mol Cell Probes; 2015 Feb 15; 29(1):54-62. PubMed ID: 25483260
    [Abstract] [Full Text] [Related]

  • 14. Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab.
    Villar LM, Costa-Frossard L, Masterman T, Fernandez O, Montalban X, Casanova B, Izquierdo G, Coret F, Tumani H, Saiz A, Arroyo R, Fink K, Leyva L, Espejo C, Simó-Castelló M, García-Sánchez MI, Lauda F, Llufriú S, Álvarez-Lafuente R, Olascoaga J, Prada A, Oterino A, de Andrés C, Tintoré M, Ramió-Torrentà L, Rodríguez-Martín E, Picón C, Comabella M, Quintana E, Agüera E, Díaz S, Fernandez-Bolaños R, García-Merino JA, Landete L, Menéndez-González M, Navarro L, Pérez D, Sánchez-López F, Serrano-Castro PJ, Tuñón A, Espiño M, Muriel A, Bar-Or A, Álvarez-Cermeño JC.
    Ann Neurol; 2015 Mar 15; 77(3):447-57. PubMed ID: 25581547
    [Abstract] [Full Text] [Related]

  • 15. Immunological biomarkers identifying natalizumab-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy.
    Serana F, Chiarini M, Sottini A, Bertoli D, Giustini V, Tessitore MV, Caimi L, Capra R, Imberti L.
    J Neuroimmunol; 2014 Dec 15; 277(1-2):6-12. PubMed ID: 25468273
    [Abstract] [Full Text] [Related]

  • 16. [[Natalizumab therapy, 2013].
    Karácsony M, Bencsik K, Vécsei L.
    Ideggyogy Sz; 2014 Jul 30; 67(7-8):220-8. PubMed ID: 25509362
    [Abstract] [Full Text] [Related]

  • 17. Changes in JC virus-specific T cell responses during natalizumab treatment and in natalizumab-associated progressive multifocal leukoencephalopathy.
    Perkins MR, Ryschkewitsch C, Liebner JC, Monaco MC, Himelfarb D, Ireland S, Roque A, Edward HL, Jensen PN, Remington G, Abraham T, Abraham J, Greenberg B, Kaufman C, LaGanke C, Monson NL, Xu X, Frohman E, Major EO, Douek DC.
    PLoS Pathog; 2012 Jul 30; 8(11):e1003014. PubMed ID: 23144619
    [Abstract] [Full Text] [Related]

  • 18. Study of the anti-JCV antibody levels in a Spanish multiple sclerosis cohort.
    Dominguez-Mozo MI, Rus M, Santiago JL, Izquierdo G, Casanova I, Galan V, Garcia-Martinez MA, Arias-Leal AM, García-Montojo M, Pérez-Pérez S, Arroyo R, Alvarez-Lafuente R.
    Eur J Clin Invest; 2017 Feb 30; 47(2):158-166. PubMed ID: 28036121
    [Abstract] [Full Text] [Related]

  • 19. Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.
    Bartt RE.
    Curr Opin Neurol; 2006 Aug 30; 19(4):341-9. PubMed ID: 16914971
    [Abstract] [Full Text] [Related]

  • 20. Modeling probability of additional cases of natalizumab-associated JCV sero-negative progressive multifocal leukoencephalopathy.
    Carruthers RL, Chitnis T, Healy BC.
    Mult Scler; 2014 May 30; 20(6):757-60. PubMed ID: 24189572
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.